The short answer
Do not self-start kava during lofexidine treatment. Kava guidance advises against combining it with sedating substances, and lofexidine can increase sedation. The exact pair’s risk has not been quantified.
What this answer covers
Oral Piper methysticum products; extract composition and preparation vary.
- Supplement or preparation
- Piper methysticum
- Medication ingredient
- lofexidine
Why the treatment team should review it
NCCIH advises against kava with sedating substances. Lofexidine labeling warns of potentiated sedation with other sedating products. This supports caution even though the exact combination has not been tested.
A short trial did not establish benefit
A four-week controlled trial found no advantage for the tested kava intervention on its primary anxiety outcome. It did not test lofexidine, and lack of benefit does not answer the combination’s safety question.
The preparation matters beyond sedation
Kava products have also been linked to rare severe liver injury. That is a kava safety issue, not proof that lofexidine adds liver toxicity. Show the team the actual product and avoid relying on a time gap for protection.
Protect alertness during withdrawal treatment
Do not drive or use machinery if drowsy, and follow the treatment team’s advice until you know how lofexidine affects you. Tell the team about alcohol and all sleep products. Contact them if sedation becomes troublesome; lofexidine should not be abruptly stopped without a plan.
Evidence and practical considerations
Side effects & toxicity
A conditional impairment precaution is supported, without a measured exact-pair effect.
- Exact scope
- Oral Piper methysticum products; extract composition and preparation vary. with Oral lofexidine for adult opioid withdrawal; label section 11 supports hydrochloride-to-active-moiety identity.
- Medication form and route
- oral supplement unless clinician-directed electrolyte correction requires another route
- Timing or duration
- Lofexidine course is symptom-guided up to 14 days; longer supplement studies do not establish acute co-use safety.
What remains uncertain
- Kava trial efficacy results do not establish lofexidine co-use safety or a protective interval.
Factors that may matter: exact preparation; blood pressure and pulse; kidney function; other medicines; baseline electrolyte status or alertness.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Adults receiving treatment for opioid withdrawal symptoms.
Can cause hypotension, bradycardia, syncope and sedation. Avoid medicines lowering pulse or pressure; potentiates benzodiazepine CNS depression and is expected to potentiate other sedating drugs. Correct hypokalemia/hypomagnesemia first and monitor ECG at initiation in those patients because lofexidine prolongs QT. Abrupt discontinuation can raise blood pressure.
How this applies: RxNorm 28863 IN maps to this SPL; section 11 confirms salt-to-active-moiety identity. Applies to prescribed oral lofexidine for adult opioid withdrawal, not another alpha-2 agonist.
Does not establish supplement depletion, automatic supplementation, exact botanical interaction rates or a safe supplement spacing interval.
Source 2: official guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: People considering the specified supplement.
Advises against use with sedative substances. Kava may cause dizziness and has been linked to rare severe liver injury, including with different extraction methods.
How this applies: Preparation-specific context; not a directly measured lofexidine interaction.
Not a lofexidine study. Intrinsic liver risk does not establish added lofexidine hepatotoxicity; preparation and co-exposure vary.
Source 3: randomized placebo-controlled trial
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 391 adults randomized to three groups in an internet-based trial.
Neither active intervention improved its primary anxiety or insomnia outcome more than placebo.
How this applies: Indirect efficacy context for tested kava and valerian preparations, not exact lofexidine safety or an unidentified valerian-root species.
Not both active botanicals together, not lofexidine co-use. Accessible abstract does not fully characterize dose and preparation; efficacy result is not proof of combination safety.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Inspected sources applied to exact current available claim; no clinical review asserted. | |
| Research summary published |
Article revision: c56d00a2c93002d5
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.